CRGX icon

CARGO Therapeutics

4.13 USD
+0.06
1.47%
Updated Apr 1, 2:58 PM EDT
1 day
1.47%
5 days
-0.96%
1 month
12.23%
3 months
-72.56%
6 months
-77.39%
Year to date
-72.56%
1 year
-80.91%
5 years
-71.58%
10 years
-71.58%
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

400% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 5

106% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 18

75% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 7 (+3) [Q4]

25% more funds holding

Funds holding: 79 [Q3] → 99 (+20) [Q4]

15.72% more ownership

Funds ownership: 101.98% [Q3] → 117.7% (+15.72%) [Q4]

10% less capital invested

Capital invested by funds: $865M [Q3] → $781M (-$84.1M) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$3
27%
downside
Avg. target
$4.67
13%
upside
High target
$7
69%
upside

3 analyst ratings

positive
0%
neutral
100%
negative
0%
Truist Securities
Asthika Goonewardene
22% 1-year accuracy
5 / 23 met price target
69%upside
$7
Hold
Downgraded
30 Jan 2025
Piper Sandler
Biren Amin
17% 1-year accuracy
4 / 24 met price target
3%downside
$4
Neutral
Downgraded
30 Jan 2025
Jefferies
Michael Yee
20% 1-year accuracy
2 / 10 met price target
27%downside
$3
Hold
Downgraded
30 Jan 2025

Financial journalist opinion

Based on 4 articles about CRGX published over the past 30 days

Neutral
GlobeNewsWire
1 week ago
CARGO Therapeutics Provides Corporate Update
- Development of CRG-023 and allogeneic platform suspended; further reduction in force (RIF) of approximately 90% to preserve cash and maximize shareholder value - - CARGO had cash, cash equivalents and marketable securities of $368.1 million as of December 31, 2024 - - Anup Radhakrishnan appointed as interim CEO to pursue reverse merger or other business combination - SAN CARLOS, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX) today provided an update regarding its ongoing evaluation of strategic options following the discontinuation of FIRCE-1, a Phase 2 study of firicabtagene autoleucel (firi-cel).
CARGO Therapeutics Provides Corporate Update
Neutral
Accesswire
4 weeks ago
An Investigation Has Commenced on Behalf of CARGO Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your CRGX Losses.
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.
An Investigation Has Commenced on Behalf of CARGO Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your CRGX Losses.
Neutral
Accesswire
4 weeks ago
Lost Money on CARGO Therapeutics, Inc.(CRGX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESS Newswire / March 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.
Lost Money on CARGO Therapeutics, Inc.(CRGX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
Neutral
Accesswire
4 weeks ago
An Investigation Has Been Launched Into CARGO Therapeutics, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ:CRGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
An Investigation Has Been Launched Into CARGO Therapeutics, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Neutral
Accesswire
1 month ago
CARGO Therapeutics, Inc. (CRGX) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESS Newswire / March 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.
CARGO Therapeutics, Inc. (CRGX) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
Neutral
Accesswire
1 month ago
The Schall Law Firm Invites Shareholders With Losses In CARGO Therapeutics, Inc. To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ:CRGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Invites Shareholders With Losses In CARGO Therapeutics, Inc. To Join A Securities Fraud Investigation
Neutral
Accesswire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CARGO Therapeutics, Inc - CRGX
NEW YORK CITY, NY / ACCESS Newswire / March 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("Cargo" or the "Company") (NASDAQ:CRGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CARGO Therapeutics, Inc - CRGX
Neutral
Accesswire
1 month ago
Levi & Korsinsky Reminds Shareholders of an Investigation into CARGO Therapeutics, Inc. (CRGX) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.
Levi & Korsinsky Reminds Shareholders of an Investigation into CARGO Therapeutics, Inc. (CRGX) Regarding Potential Securities Fraud Allegations
Neutral
Accesswire
1 month ago
An Investigation Has Been Launched Into CARGO Therapeutics, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / February 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ:CRGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
An Investigation Has Been Launched Into CARGO Therapeutics, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Neutral
Accesswire
1 month ago
CRGX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by CARGO Therapeutics, Inc.
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.
CRGX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by CARGO Therapeutics, Inc.
Charts implemented using Lightweight Charts™